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RESEARCH ARTICLE
M€uller Glia as an Important Source
of Cytokines and Inflammatory Factors
Present in the Gliotic Retina During
Proliferative Vitreoretinopathy
K. Eastlake,1 P. J. Banerjee,1 A. Angbohang,1 D. G. Charteris,2
P. T. Khaw,2 and G. A. Limb2
Retinal gliosis is characterized by biochemical and physiological changes that often lead to M€uller glia proliferation and hyper-
trophy and is a feature of many neuro-degenerative and inflammatory diseases such as proliferative vitreoretinopathy (PVR).
Although M€uller glia are known to release inflammatory factors and cytokines, it is not clear whether cytokine production by
these cells mirrors the pattern of factors present in the gliotic retina. Lysates from normal cadaveric retina and gliotic retinal
specimens from patients undergoing retinectomy for treatment of PVR, the M€uller cell line MIO-M1 and four human M€uller
glial cell preparations isolated from normal retina were examined for their expression of cytokines and inflammatory factors
using semi-quantitative dot blot antibody arrays and quantitative arrays. Comparative analysis of the expression of inflamma-
tory factors showed that in comparison with normal retina, gliotic retina exhibited greater than twofold increase in 24/102 fac-
tors examined by semiquantitative arrays, and a significant increase in 19 out of 27 factors assessed by quantitative methods
(P< 0.05 to P<0.001). It was observed that with the exception of some chemotactic factors, the majority of cytokines and
inflammatory factors were produced by M€uller glia in vitro and included G-CSF, MCP-1, PDGF-bb, RANTES, VEGF, and
TGFb2. These results showed that a large number of inflammatory factors expressed by M€uller glia in vitro are upregulated in
the gliotic retina, suggesting that targeting the production of inflammatory factors by M€uller glia may constitute a valid
approach to prevent neural damage during retinal gliosis and this merits further investigations.
GLIA 2016;64:495–506
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Introduction
Events leading to the development of PVR, a commoncomplication of retinal detachment, have been associated
to those of the inflammatory and wound healing responses
(Garweg et al., 2013; Oberstein et al., 2011). Cellular proc-
esses leading to the development of PVR involve migration
and proliferation of a variety of cells including retinal pig-
ment epithelium (RPE) (Hiscott et al., 1999), mononuclear
leucocytes (Hiscott et al., 1989; Limb et al., 1993), microglia
(Weller et al., 1991a,b), and M€uller glia (Bringmann et al.,
2009), all of which are known to contribute to inflammation
by releasing proinflammatory factors and cytokines. Although
retinal pigment epithelial (RPE) cell proliferation was thought
for a long time to be the major player in the development of
PVR (Kirchhof and Sorgente, 1989; Palma-Nicolas et al.,
2010; Parrales et al., 2013), in recent years it has been
accepted that M€uller glia also play a very important role in
the pathogenesis of this condition (Bringmann et al., 2009;
Charteris et al., 2007; Guidry, 2005; Lewis et al., 2010; Mor-
escalchi et al., 2013; Velez et al., 2012).
M€uller glia span across the whole width of the retina
and provide structural and metabolic support to retinal neu-
rons (Bringmann and Wiedemann, 2012). Whilst there is evi-
dence that M€uller glia become progenitor cells in fish and
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amphibians in response to retinal damage (Lenkowski et al.,
2013), in the adult mammalian retina this feature appears to
have been lost (Loffler et al., 2015). In contrast, reactive M€uller
cell gliosis characterized by morphological, biochemical, and
physiological changes, often occurs in the mammalian retina in
response to injury (Bringmann et al., 2006). This process is
thought to develop as a protective mechanism to prevent fur-
ther damage to the retina and to promote tissue repair. Yet, it
does not appear to be beneficial in the adult mammalian retina
and it has been thought that the release of proinflammatory
cytokines and growth factors from M€uller glia, can lead to fur-
ther degeneration (Bringmann and Wiedemann, 2012).
Several growth factors, cytokines, and matrix degrading
enzymes are observed in vitreous, subretinal fluid, and retinal tis-
sue from eyes affected by PVR (Lei et al., 2010; Limb et al.,
1991, 1994; Symeonidis et al., 2014). Infiltrating macrophages
and local microglia are thought to secrete growth factors, which
in turn promote further cytokine production and cellular migra-
tion and differentiation (Weller et al., 1990), whilst RPE cells
have been thought to be responsible for the production of extrac-
ellular matrix (Hiscott et al., 1999), as well as various proinflam-
matory cytokines, including transforming growth factor b2
(Hirsch et al., 2015). M€uller glia have been shown to release sev-
eral inflammatory factors and cytokines (Bringmann et al., 2009)
and some cytokines in turn have been shown to stimulate pro-
duction of other cytokines by M€uller glia (Yoshida et al., 2001).
In addition, M€uller glia express toll-like receptors (TLRs) (Kumar
et al., 2013) and receptors for advanced glycation end products
(RAGE) (Zong et al., 2010) that upon binding to their ligands
induce production of proinflammatory cytokines, chemokines
and neuroprotective growth factors by these cells.
Although various cytokines and growth factors have
been identified in vitreous and retinal tissues from many reti-
nal conditions associated with gliosis (Chua et al., 2012;
Franks et al., 1992; Limb et al., 1991, 1994; Muether et al.,
2013; Suzuki et al., 2011), it is not clear to what extent
M€uller glia may contribute to the release of factors present in
the gliotic retina, and whether the pattern of cytokine expres-
sion in the gliotic retina may mimic that of isolated M€uller
cells. It was therefore the aim of this study to investigate the
expression of a range of proinflammatory factors in M€uller
glia in vitro and to examine whether this expression parallels
that seen in the gliotic retina from patients with proliferative
vitreoretinopathy (PVR).
Materials and Methods
Tissue and Cell Culture
Four retinal specimens isolated from normal cadaveric donors were
obtained from Moorfields eye Bank, with prior consent for research.
All eyes were obtained within 24-h post mortem and the age range of
the donors was 34–88 years. The eyes were kept in sterile saline and
retinas carefully removed and washed in PBS. Specimens for protein
analysis were obtained by excising sections of peripheral retina between
1–3 mm 3 1–5 mm (3–5 mm2) to match the size of the retinectomy
specimens obtained. Samples were then frozen at 2808C until use. Six
peripheral retinectomy specimens (3–5 mm2) from eyes undergoing
retinal surgery for treatment of proliferative vitreo-retinopathy (PVR)
were obtained from Moorfields eye Hospital, upon written consent
from the patients. The age of the patients ranged between 58 and 71
years, with a duration of PVR of 2–10 weeks. All tissues used in this
study were obtained and treated according to guidelines from the Local
Ethics Committee at Moorfields and the Institute of Ophthalmology
and followed the tenets of the Declaration of Helsinki. Isolated retinas
were washed in PBS and frozen at 2808C until use.
The M€uller cell line (MIO-M1) established in our laboratory
and derived from normal retinae (Limb et al., 2002), and other four
M€uller cell preparations isolated as previously described (Limb et al.,
2002) were used in the study. These were named 6387, 6391, 6390,
and 6426. Although they were used between passages 9 and 14,
these cells have the characteristics of the MIO-M1 cell line, and
upon further passages they have been shown to be spontaneously
immortalized. Each cell preparation was grown to a confluent mono-
layer on plastic flasks in DMEM containing 10% FCS. Monolayers
were washed in PBS and detached from tissue culture flasks using a
cell scraper. Cells were resuspended in PBS and centrifuged to obtain
a cell pellet. This was then frozen at 2808C until use.
Preparation of Retina and Cell Lysates
Cell lysis was carried out in retinal specimens and M€uller cell pellets
using a BioPlex cell lysis kit (171-304011, BioRad, UK) according
to the manufacturer’s instructions. Briefly, samples were rinsed with
cell wash buffer, and homogenized in 500 lL cell lysis solution (con-
taining 500 mM PMSF). Samples were then frozen at 2708C,
thawed and sonicated on ice followed by centrifugation at 4,500g for
4min (cell lysates) or 20 min (retina samples). Supernatants contain-
ing proteins were collected and protein concentrations were deter-
mined using a BCA assay kit (Thermo Fischer, UK).
Proteome Profiler Antibody Array
The R&D Systems Human XL cytokine array kit (ARY022, R&D
Systems, UK) was used to perform a general semi quantitative analy-
sis of various cytokines expressed in normal and gliotic human reti-
nal lysates as well as cultured M€uller glia lysates. Protocols were
followed as per manufacturer’s instructions. Because of the small size
of the gliotic and normal retinal specimens investigated (3–5 mm2),
it was necessary to pool the protein lysates of gliotic or normal retina
to yield the protein concentrations of 150 lg mL21 required for the
assay. A pool of M€uller cell lysates was also made in order to under-
take a comparative analysis between samples.
Protein extracts of cell and retinal samples were incubated
with the antibody array membranes overnight at 48C. After washing,
membranes were incubated with detection antibodies and chemilu-
minescent reagents provided in the kit. Membranes were protected
in plastic sheeting before imaging using an autoradiography cassette
and X-ray film. Spot intensity analysis was carried out using ImageJ
and Microsoft Excel.
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Quantitative Analysis of Cytokines and
Growth Factors
The BioPlex-pro 27 plex immunoassay (BioRad, UK), which pro-
vides quantitative values, was used in this study to confirm results
from the proteome profiler array. Experiments were carried out fol-
lowing the manufacturer’s instructions. Using the protein standards
provided, six gliotic retinal samples, four normal cadaveric retinae,
and five different M€uller cell preparations including the MIO-M1
cell line, were each prepared to contain between 200 and 900
lg mL21 protein and individually examined in the immunoassay. In
addition, each individual sample was assessed in duplicate. The mag-
netic bead stock was diluted 1:20 with assay buffer and 50 lL of
this solution was loaded into each well of a 96-well plate. Beads
were washed twice in wash buffer using a Bio-PlexVR Handheld Mag-
netic Washer (#171-020100, BioRad). The standards and samples
were then loaded in duplicate into the wells and the plate was sealed
and incubated at room temperature for 2 h. After the incubation,
the plate was rinsed with wash buffer three times using the magnetic
plate, before addition of 25 lL of detection antibodies. After 1-h
incubation on the shaker, the plate was washed three times, and 50
lL of streptavidin added to each well. The plate was then incubated
for 30 min on the shaker and washed three times. About 125 lL of
assay buffer was added to each well and the plate incubated for 30 s
before reading on the BioPlex MagpixTM(BioRad,UK) system. Cyto-
kines detected in this array included FGFb, Eotaxin, G-CSF, GM-
CSF, IFN-g, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,
IL-10, IL-12 (p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1a,
MIP-1b, PDGF-BB, RANTES, TNF-a, and VEGF. Tests were also
performed to analyse the three isoforms of TGF beta, using the
BioPlex-pro TGFbeta 3-plex immunoassay (BioRad,UK). Because
TGFb is normally produced as a high molecular weight protein
complex consisting of a mature TGFb dimer, the latency-associated
peptide (LAP) and the latent TGFb binding protein (LTBP), tran-
sient acidification followed by neutralization is needed to release the
immunoreactive form for quantification. Because this treatment
affects the quantification of most cytokines, it is necessary to under-
take specific assays for TGFb (Kropf et al., 1997). Therefore, for the
TGFb analysis, lysates of six gliotic retina, four normal retina, or
M€uller cells were activated with 1N HCl, followed by neutralization
with 1.2N NaOH/0.5 M HEPES buffer prior to performing the
assay described above. The same procedure was followed to assess
the cell culture supernatants of MIO-M1 cells, which were examined
as single specimens. Mean cytokine values of individual samples
were obtained using the BioPlex manager 6.1 (BioRad,UK) and
Microsoft Excel programmes. Statistical comparison between differ-
ent groups was determined by two tailed, unpaired t tests, using the
GraphPad Prism5 programme.
Results
Expression of Cytokines and Growth Factors by
M€uller Glial Cell Preparations
Semiquantitative analysis of a pool of lysates from the five dif-
ferent M€uller cell preparations used in the study detected the
presence of 76 factors out of the 102 examined. The cytokines
and growth factors predominantly observed were those associ-
ated with retinal differentiation (EGF), axon regeneration
(osteopontin) proliferation (DPPIV, MIF, EGF, PDGF-aa,
FGF-19) matrix organization (Serpin E1, EMMPRIN, uPAR,
DPPIV), inflammation (Pentraxin-3, GM-CSF, MIF, IL-1RA,
IL-17a), and apoptosis (GM-CSF, myeloperoxidase, MIF, Ser-
pinE1). Basal levels of other proinflammatory cytokines and
chemokines including IL-6, M-CSF, MIP-3a, IL-15, MCP-3,
TNFa, MIP-1a/b, and matrix components such as thrombo-
spondin were also detected at very low levels (Fig. 1).
Further examination of the expression of cytokines in
the MIO-M1 cell line and four different M€uller glial cell
lysates by quantitative methods (BioPlex Pro) showed that
these cells expressed all the 27 cytokines analyzed, although
some cytokines were found to be present in the cell lysates at
very low levels. FGFb consistently exhibited the highest
expression levels in all M€uller glial samples at 1–2 pg lg21
FIGURE 1: Expression of cytokines and growth factors by M€uller
glia in vitro. Images show the relative expression of cytokines
and growth factors detected in a pooled lysate from the five dif-
ferent M€uller glia cell lines investigated. (A) Dot blot membrane
array shows the intensity of expression of the various factors in
the cell lysate. Spots marked by black boxes indicate positive
controls, whilst spots marked by the white box indicate the neg-
ative controls. (B) Histograms show in descending order the rela-
tive levels of cytokines and growth factors expressed by M€uller
glia. Values were normalized to the positive controls. Relative
values below 0.1 were excluded from the analysis.
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protein (Fig. 2). Expression levels largely related to the semi-
quantitative analysis (Fig. 1) and showed high concentrations
of GM-CSF, MCP-1, and G-CSF. Many factors showing low
expression (below 0.4 pg lg21 protein) in the quantitative
array also showed low expression in the semiquantitative array
and included PDGF-bb, IL-12, IL-15, IL-6, IL-10, IL-13,
IL-2, IL-4, IL-17a, IL-1b, IL-1ra, TNF-a, MIP-1b, and
MIP-1a. Unlike most cytokines which were present in all the
cell lines examined, IL-15 was only observed in two out of
five cell preparations.
Quantitative analyses of five M€uller glial cell lysates
were performed to assess the expression of the three different
isoforms of TGFb. It was observed that all the five M€uller
glial cell preparations investigated expressed relatively higher
levels of TGFb1 (0.646 0.33 pg lg21 protein) than TGFb2
(0.236 0. 0.1 pg lg21 protein) (P5 0.02) or TGFb3
(0.016 0.001 pg lg21 protein) (P< 0.001) (Fig. 3A).
TGFb3 was only observed above detectable levels in two out
of the five cell preparations analyzed (MIO-M1 and 6387).
Quantification of TGFb protein isoforms 1, 2, and 3 in a
culture supernatant of the MIO-M1 cell line showed that
TGFb1 was the predominant isoform released (1713
pg mL21), followed by TGFb2 (1093 pg mL21). In contrast,
very low levels of TGFb3 (15.25 pg mL21) were observed in
the supernatant of these cells (Fig. 3B). The levels of TGFb
isoforms observed in the supernatant of MIO-M1 cells were
related to the levels of these cytokines detected in the cell
lysates (Fig. 3A).
FIGURE 2: Expression of cytokines and growth factors by M€uller
glia in vitro as determined by quantitative analysis. Histogram
shows the quantitative analysis of the expression of cytokines in
the five different M€uller cell lysates examined. Levels are shown
in descending order according to the levels observed in the
majority of cells.
FIGURE 3: Expression of TGFb isoforms by M€uller glia in vitro.
(A) Histograms show the mean value of the levels of expression
of TGFb1, TGFb2, and TGFb3 in each of the individual M€uller
glial cell lysates investigated, as determined by a quantitative
immunoassay. All the cell lysates examined expressed higher lev-
els of TGFb1 as compared with TGFb2 (unpaired two-tailed t
test, P50.02) and TGFb3 (unpaired two-tailed t test, P<0.001).
Very low levels of TGFb3 were only detected in MIO-M1 and
6387 cells. (B) Quantitative analysis of the TGFb isoforms present
in individual cell culture supernatant of the M€uller cell line MIO-
M1 shows that TGFb1 and TGFb2 are released by these cells in
similar proportion to that seen in cell lysates. Minimally detecta-
ble levels of TGFb3 were released by these cells.
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Comparison of the Expression of Cytokines and
Growth Factors Between Gliotic Retina of
Proliferative Vitreoretinopathy and Normal Retina
Semiquantitative analysis of a pool of six PVR specimens and
four retinal fragments from normal cadaveric retina detected
the presence of 82 factors out of 102 examined (Fig. 4). All
the cytokines and growth factors identified in the normal ret-
ina were also present in the gliotic retina. However, 21 of
these factors were found >2-fold upregulated in the gliotic
retina as compared with normal retina, whilst five of these
factors were <0.6-fold downregulated in the gliotic retina as
compared with normal retina (Table 1). Factors including
TFF3, I-TAC, and IL-16 exhibited the highest fold increase
in the gliotic retina when compared with normal retina
(Table 1). As expected, inflammatory cytokines such as IL-1a,
VEGF, PF4, IL-16, PDGF-AA/BB, M-CSF, adiponectin,
MIP-3b, IL-18bpa, I-TAC, and IL-2 also exhibited a two-
fold increase in the gliotic retina compared with normal ret-
ina. Factors involved in metabolic regulation such as adipo-
nectin was also upregulated more than two-fold in the gliotic
retina as compared with normal retina. Factors found to be
two-fold downregulated in the gliotic retina compared with
normal retina included angiogenin, C-reactive protein, myelo-
peroxidase, MMP-9 and aggrecan (Table 1).
Further analysis by quantitative methods compared the
levels of 27 cytokines and growth factors between lysates
derived from normal cadaveric retina (n5 4) and gliotic ret-
ina obtained from patients with PVR (n5 6). FGF basic,
FIGURE 4: Semi-quantitative analysis of the expression of cytokines and growth factors in gliotic and normal human retina. Images show
the relative expression of cytokines and growth factors detected in pooled lysates from four normal cadaveric retina and six gliotic reti-
nectomy specimens. (A, B) Dot blot membrane arrays show the intensity of expression of various factors in the retinal lysates. Spots
marked by black boxes indicate positive controls, whilst spots marked by the white box indicate the negative controls. (C). Histograms
show in descending order the levels of expression of the various factors in the pooled specimens. Values were normalized to the posi-
tive controls. Relative values below 0.1 were excluded from the analysis.
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GM-CSF and IP-10 showed high expression in the retinal
lysates in comparison to other cytokines analyzed. No expres-
sion of IL-15 was detected in any of the retinal lysates ana-
lyzed. A significant increase, was observed in 19 out of the 27
cytokines investigated quantitatively in the gliotic retina as
compared with the normal retina and included GM-CSF,
G-CSF, VEGF, RANTES, MCP-1, PDGF-bb, IL-9, IL-17a,
IL-12, IL-1ra, IL-10, MIP-1b, IL-8, TNFa, IL-6, IL-13, IL-2,
IL-4, MIP-1a, and IL-1b (P< 0.05 to P< 0.001; two tailed
t test) (Fig. 5).
Quantitative expression of the three different TGFb iso-
forms was compared between six gliotic retinal specimens and
four normal retinae. TGFb2 was the predominant isoform
present in the lysates from both gliotic and normal human
retinae (Fig. 6). TGFb2 was the only isoform to be signifi-
cantly increased in the gliotic retina as compared with the
normal retina (P< 0.01). Although an increase in the levels
of TGFb1 was observed in the gliotic retina as compared
with normal retina these levels were not significantly differ-
ent. In addition, TGFb3 which was not observed in the
TABLE 1: Semi-quantitative Analysis of the Expression of Cytokines and Inflammatory Factors in PVR Retina as Com-
pared with Normal Retina
Factor Function Fold change
(gliotic/normal retina)
TFF3 Cell growth, metastasis, and angiogenesis 4.623920
I-TAC Chemokine 3.725999
IL-16 Cytokine/chemoattractant 3.209796
IL-18 Bpa Inhibits IL-18 2.975417
DPPIV Antigenic enzyme 2.748755
uPAR Glycoprotein/receptor 2.747772
IL-1a Pro-inflammatory cytokine 2.611321
PF4 Chemokine–blood coagulation 2.595450
MIP-3b Chemokine 2.530014
TfR Carrier protein; iron import 2.487686
VEGF Growth factor–vasculogenesis 2.460055
IL-23 Pro-inflammatory cytokine 2.435597
M-CSF Pro-inflammatory cytokine 2.371067
adiponectin Hormone; glucose regulation 2.357242
IL-2 Pro-inflammatory cytokine 2.259597
ENA-78 Chemokine 2.237109
PDGF-AB/BB Growth factor 2.211187
SDF-1a Chemokine 2.185202
pentraxin-3 Immune regulation 2.175439
Kallikrein Enzyme; proinflammatory 2.107335
Resistin Hormone; proinflammatory 2.049007
aggrecan Cartilage proteoglycan 0.575574
angiogenin Enzyme; angiogenesis 0.500763
C-reactive protein Proinflammatory 0.466765
MMP-9 Matrixin enzyme 0.408317
Myeloperoxidase Lysosomal enzyme 0.366569
Values obtained from semiquantitative analysis of dot blot arrays showing the fold change in the expression of cytokines and growth factors
in the gliotic retina as compared with the normal retina. Values below 0.1 were excluded from analysis.
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normal retina, was observed in two of the six gliotic speci-
mens analyzed (Fig. 6).
Comparison of the Expression of Cytokines
Between M€uller Glia and Gliotic or Normal Retina
Semiquantitative analysis revealed various similarities and dif-
ferences in the expression of cytokines and growth factors
between M€uller glia and retinal specimens. Of the 95 proteins
identified by the protein array, 76 (80%) were detected in
M€uller glia in vitro, whilst 83 (87%) were detected in the
normal and gliotic retina. Out of the 76 proteins expressed
by M€uller glia, only 12 (16%) were unique to these cells,
whilst 64 (84%) were also found in retinal specimens. Of the
83 proteins detected in retina, only 19 (22.9%) were unique
to gliotic or normal retina (Fig. 7). Factors including TFF3,
IL-16, DPPIV, uPAR, IL-1a, PF4, TfR, VEGF, M-CSF, adi-
ponectin, IL-2, PDGF-AB/BB, and SDF-1a, were observed
two-fold or more upregulated in the gliotic retina as com-
pared with normal retina, and shared their expression with
M€uller glia (Fig. 7). Other proteins found to be highly
expressed in the M€uller glia in vitro, including EMMRIN,
Chitinase 3 like 1, FGFb, MIF, resistin and osteopontin were
also found at high levels in both gliotic and normal retina,
although there were no differences in their expression between
these specimens (Figs. 1, 4 and 7). Aggrecan, MMP-9 and
myeloperoxidase which also shared expression between retina
and M€uller glia, were downregulated in the gliotic retina as
compared to normal retina. Of the 19 factors detected only
in retinal specimens, I-TAC, IL-18Bpa, MIP-3b, IL-23, and
ENA-78 were observed to be upregulated in the gliotic retina,
whilst angiogenin and c-reactive protein were observed down-
regulated in the gliotic retina Fig. 7).
Quantitative analysis showed that out of 27 factors ana-
lyzed, all were detected in M€uller glia in vitro. In addition, with
the exception of IL-15, which was only found in two M€uller cell
preparations, all factors were present in the retinal specimens. Of
the 26 cytokines identified in retina, 19 (70%) were significantly
upregulated (P< 0.05 to P< 0.001) in the gliotic retina as com-
pared with normal retina (Fig. 5, Table 2). Interestingly, FGFb
and GM-CSF, which were highly expressed in the gliotic retina,
were expressed at the highest levels in M€uller cell lysates.
Discussion
Inflammation has been implicated in the pathogenesis of reti-
nal gliosis from various aetiologies, including PVR, diabetic
retinopathy and prevalent diseases that lead to blindness, such
as AMD and glaucoma (Hollborn et al., 2008; Muether
FIGURE 5: Expression of inflammatory cytokines in the gliotic
and normal human retina. Histogram shows a quantitative analy-
sis of the expression of cytokines arranged in a descending order
according to the levels observed in the gliotic retina. Asterisks
denote a significant upregulation in the gliotic retina (red col-
umns) as compared with the normal retina (blue columns). Error
bars indicate the mean6SEM for each group. *P<0.05;
**P<0.01; ***P<0.001. n5number of samples investigated.
FIGURE 6: Levels of TGFb isoforms in gliotic and normal human
retina. Scatter dot-plots show the levels of expression of the
three different isoforms of TGFb in four normal and six gliotic
human retinal specimens. Error bars indicate the mean6SEM for
each group. * Unpaired two-tailed t test, P<0.05 vs. normal ret-
ina; ** unpaired two-tailed t test, P<0.01 v. normal retina.
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et al., 2013; Suzuki et al., 2011; Tezel and Wax, 2004).
Inflammatory factors and cytokines are found in the vitreous
and retinal specimens of eyes affected by various retinal
degenerative conditions (Chua et al., 2012; Limb et al.,
1991, 1994), whilst M€uller glia in vitro have been shown to
produce various inflammatory factors associated with gliosis
(Bringmann et al., 2009). Different cell types have been
implicated in the development of gliosis but it is not clear
whether cytokines present in the gliotic retina predominantly
derive from a specific cell population. Furthermore, the pat-
tern of expression of inflammatory factors in both, the gliotic
retina of PVR and isolated M€uller glia alone have not been
previously examined. This study aimed to assess whether fac-
tors produced by M€uller glia in vitro could be associated to
the high levels of cytokines and inflammatory factors present
in retinal specimens of patients with PVR.
Because of the size of the gliotic specimens obtained
(3–5 mm2), it was necessary to pool the protein lysates of
gliotic and normal retina to yield the required protein concen-
trations to undertake the protein profile array. Since we pooled
the tissue samples, a pool of protein cell lysates was also made
in order to undertake a comparative analysis between samples.
As identified by semiquantitative analysis the protein
found to be the most highly upregulated in the gliotic PVR
retina, was trefoil factor 3 (TFF3), showing a 4.2-fold increase
TABLE 2: Comparison of Inflammatory Factors
Expressed by M€uller Glia, Normal, and Gliotic Retina
Average expression (pg/lg protein)
Protein M€uller glia Normal
retina
Gliotic
retina
IL-15 0.040668 0 0
IL-1b 0.001851 0.000607 0.001695*
MIP-1a 0.003732 0.001224 0.003418**
IL-5 0.002317 0.002111 0.003855
IL-4 0.00598 0.002 0.005974*
IL-2 0.017284 0 0.00788*
Eotaxin 0.040389 0.006458 0.01172
IL-13 0.022528 0.007916 0.020591*
IL-6 0.03749 0.007552 0.024154**
TNFa 0.035241 0.012741 0.022777
IL-8 0.026798 0.006391 0.029021***
MIP-1b 0.007141 0.002183 0.023561*
IL-10 0.031976 0.002435 0.023479*
IFNg 0.096418 0.006599 0.04368
IL-1ra 0.065974 0.022479 0.062883*
IL-12 0.139451 0.014386 0.077607*
IL-17A 0.078565 0.016709 0.077919*
IL-9 0.090557 0.033561 0.101902**
PDGF-bb 0.220385 0.041872 0.105347**
MCP-1 0.486812 0.028808 0.108224**
IL-7 0.105637 0.020808 0.125765
RANTES 0.30209 0.029894 0.160456*
VEGF 0.281052 0.013774 0.167558*
G-CSF 0.488854 0.11078 0.335609*
IP-10 0.402409 0.364124 0.316521
GM-CSF 1.056891 0.332087 1.418945*
bFGF 1.590391 1.200721 1.809477
Table shows the mean expression values of various factors in
lysates of M€uller glia (n5 5), normal retina (n5 4), and gliotic
retina (n5 6). Asterisks represent the levels of significance
between normal and gliotic retina (*P< 0.05; **P< 0.01;
***P< 0.001).
FIGURE 7: Comparison of cytokine expression between M€uller
glia and gliotic or normal retina. Venn diagram shows the over-
lapped expression of cytokines between M€uller glia, gliotic, and
normal retina as detected by semi-quantitated analysis. Factors
listed in the yellow section indicate those expressed by M€uller
glia; factors listed in the green (overlapping) section indicate
those identified in M€uller glia and normal and gliotic retina,
whilst factors listed in the blue section indicate those only
detected in normal and gliotic retina. Factors highlighted in red
indicate those which were >2-fold upregulated in the gliotic ret-
ina as compared with normal retina, whilst factors highlighted in
green represent those found <0.5-fold downregulated in gliotic
retina as compared with normal retina.
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in comparison with the normal retina. This factor was also
found to be one of the predominant factors observed in cell
lysates of M€uller glia. TFF3 peptides are located to mucous
epithelia as well as nervous tissue and are involved in apoptosis,
cell migration and immune responses (Belovari et al., 2015).
In disease, TFF3 has been associated with cell growth, metasta-
sis and angiogenesis in cancer (Babyatsky et al., 2009; Kjellev,
2009) as well as with neurodegenerative disorders such as Alz-
heimer’s disease (Bernstein et al., 2015). This protein has never
been associated to retinal gliosis and its precise role in inflam-
matory processes affecting the retina is not known. It is possi-
ble that it may contribute to the abnormal proliferation and
immune modulation of M€uller glia within the affected retina
and merits further investigations. The second most upregulated
factor found ion the gliotic retina was the interferon-inducible
T Cell Alpha Chemoattractant (I-TAC), also known as Che-
mokine (C-X-C motif) ligand 11 (CXCL11) (Rani et al.,
1996) showing a 3.7-fold increase as compared with the nor-
mal retina. Because T lymphocyte infiltration is often observed
in retinal membranes of PVR (Limb et al., 1993), this factor
may therefore be responsible for this effect. Interestingly, this
factor was not expressed by M€uller glia in vitro, suggesting that
resident or inflammatory microglia or macrophages are respon-
sible for its production within the inflamed retina. Other cyto-
kines found >2-fold upregulated in the gliotic retina included
those that function as chemoattractants, such as IL-16, platelet
factor 4 (PF4) and MIP-3b, as well as proinflammatory
cytokines such as IL-1a, and VEGF. However, most chemoat-
tractants were expressed by M€uller glia at very low levels, sug-
gesting that although M€uller glia contributes to the production
of these factors in PVR, other cells in the retina, including
microglia may also constitute a source of these cytokines. Inter-
estingly, the antigenic enzyme DPPIV, a membrane anchored
ecto-protease identified as the leukocyte antigen CD26 (Augus-
tyns et al., 1999), uPAR, a glycoprotein bound to the cell
membrane and a component of the plasminogen activation sys-
tem (Kjaergaard et al., 2008), and the transferrin receptor
(TfR), which were all present at high levels in M€uller cell
lysates were also found to be >2-fold upregulated in the PVR
retina.
Quantitative analyses identified high expression of
FGFb, GM-CSF, IP-10, and G-CSF in the normal retina,
with GM-CSF and G-CSF showing significant upregulation
in the PVR specimens. Other cytokines found in the normal
retina at relatively low concentrations, such as VEGF,
RANTES, IL-7, MCP-1, and PDGF-bb were also signifi-
cantly increased in the gliotic retina as compared with the
normal retina. This is supported by several findings in the lit-
erature, which show high upregulation of these factors in
PVR, and diabetic retinopathy (Mitamura et al., 2001; Suzuki
et al., 2011). Although these factors were highly expressed by
the five different M€uller cell preparations investigated, it is
known that factors such as VEGF can be produced by micro-
glia and macrophages (Krause et al., 2014; Liu et al., 2015),
whilst the chemokines RANTES and MCP-1 can be pro-
duced by astrocytes, microglia, and damaged neurons within
the injured CNS (Gyoneva and Ransohoff, 2015). Neverthe-
less, these results suggest that M€uller glia, which we derived
from donors with no known retinal diseases, have the poten-
tial to contribute to the expression of these factors during ret-
inal gliosis.
Semiquantitative arrays showed that the proinflamma-
tory enzyme myeloperoxidase was highly downregulated in
the PVR retina as compared with the normal retina. This
enzyme is involved in catalysing the formation of reactive
oxygen species that contribute to inflammation. High levels
have been associated with cardiovascular disease (Nicholls and
Hazen, 2005) and multiple sclerosis (Gray et al., 2008), high-
lighting the contribution of this enzyme to retinal gliosis.
Although this enzyme was observed in M€uller cell lysates, the
significance of its downregulation during retinal gliosis is yet
to be defined. It may be possible that the decrease observed
in the PVR retina was merely due to retinal cell death, or to
regulatory mechanisms triggered during retinal inflammation
that inhibit the production of this enzyme. Other factors
found to be downregulated in the gliotic retina as compared
with the normal retina include angiogenin, the matrixin
enzyme MMP-9, and proinflammatory C-reactive protein.
Angiogenin is a secreted ribonuclease that promotes RNA
transcription and cell growth. It was first identified as an
angiogenic factor produced by tumor cells and is thought to
promote cell and tissue adaptation (Lai et al., 2015). That
this protein is highly downregulated in the gliotic retina as
compared with the normal retina, may reflect the limited pro-
liferative and regenerative ability of the cells present in the
gliotic tissue. MMP-9 is involved in the degradation of the
extracellular matrix (ECM) that promotes tissue remodelling
(Vandooren et al., 2013), therefore the downregulation of
this enzyme in PVR retina may contribute to the progression
of gliosis by stabilising the ECM. C-reactive protein (CRP) is
an acute-phase protein of hepatic origin that increases follow-
ing interleukin-6 secretion from macrophages and T-cells
(Worthmann et al., 2015). This protein is rapidly produced
in response to inflammatory signals but quickly declines after
a short period (Povoa, 2002), for which it can be suggested
that its low levels in the gliotic retina may reflect the chronic-
ity of PVR. Because C-reactive protein was not shown to be
present in M€uller lysates, this may indicate that other retinal
inflammatory cells may be producing this protein during
gliosis.
The factor found to be the most abundant in the M€uller
cell lysates as judged by semiquantitative analysis, and has not
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been previously detected in M€uller glia, was the plasminogen
activator inhibitor 1 (serpin E1). Serpin E1, an inhibitor of
fibrinolysis and matrix metalloproteinases, has been implicated
in inflammatory diseases contributing to the progression of
fibrosis (Loskutoff and Quigley, 2000). However, it was not
found to be one of the predominant factors in the lysates of
normal and gliotic human retina. Another matrix-associated
protein, the extracellular matrix metalloproteinase inducer
(EMMPRIN), was also found to be abundant in M€uller glia
and although it was present at relatively high levels in the reti-
nal lysates, there was no difference in expression between the
gliotic and normal retina. That not all the factors examined
were detected in both, isolated M€uller glia and retinal speci-
mens may be due to the fact that M€uller cells in culture may
de-differentiate and lose many of their typical physiological
and functional features upon in vitro culture. Although in gli-
otic PVR retina there is severe loss of retinal neurons and pre-
dominance of reactive M€uller glia expressing GFAP and
CRALBP (Charteris et al., 2007; Ghosh and Johansson, 2012;
Wickham et al., 2007), it is possible that factors expressed by
M€uller glia may be under-represented in the retinal samples
due to the presence of other retinal cell types.
TGFb signalling is well known for its role in promoting
M€uller glia proliferation (Close et al., 2005), and is thought to
contribute to the gliotic response observed in retinal degenera-
tions (Guerin et al., 2001). Quantitative analysis of the three
TGFb isoforms identified TGFb1 as the predominant isoform
produced by M€uller glia in vitro, its values being on average
38% higher than those of TGFb2. In contrast, TGFb2 was the
predominant isoform detected in normal retina, being 2.7 times
the levels of TGFb1. In addition, TGFb2 was the only isoform
to be significantly upregulated in the PVR retina as compared
with the normal retina (P< 0.05). It has been documented that
M€uller glia in culture produce TGFb2 and that this cytokine
inhibits the proliferation of retinal endothelial cells (Yafai et al.,
2014). It is of interest that our results showed that M€uller glia
produces comparable levels of TGFb2 to those previously
reported (Yafai et al., 2014). However, a comparison between
the three different isoforms of TGFb production by M€uller glia
has not been previously shown. From the present observations it
is possible to suggest that some of the TGFb2 produced by
M€uller glia may account for the high levels present in the gliotic
retina, but it is also likely that cells other than M€uller glia may
constitute an additional source of this cytokine within the gliotic
retina. This imbalance might contribute to the progression of
the gliotic response and merits further investigations.
In conclusion, this study showed that the pattern of
expression of the majority of cytokines and proinflammatory
factors found to be significantly elevated in lysates of PVR
retina as compared with normal human retina parallels the
pattern of expression of these factors expressed by M€uller glia
in culture. That the majority of factors identified in cultured
M€uller glia by semi quantitative and quantitative analyses
were detected in retinal specimens (87 and 96%, respectively),
and that 70% of the quantitated factors were significantly
upregulated in the gliotic retina, as compared with normal
retina, strongly suggest that M€uller glia is an important
source of cytokines and growth factors associated with retinal
gliosis in PVR. Targeting the production of these factors by
M€uller glia may constitute a valid approach to prevent neural
damage during many retinal diseases and this merits further
investigations.
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